ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The RNA-binding protein ANGEL2 is implicated in cancer chemoresistance and patient survival.
• The precise mechanisms by which ANGEL2 influences cancer progression and chemoresistance remain largely undetermined.

Purpose of the Study:

• To elucidate the mechanism by which ANGEL2 modulates cancer progression and chemoresistance.
• To investigate the role of ANGEL2 in regulating the translation of the tumor suppressor protein TP53.

Main Methods:

• Investigated the interaction between ANGEL2 and EIF4E (eukaryotic translation initiation factor 4E).
• Assessed the impact of ANGEL2 on the interaction between EIF4E and the TP53 translation repressor RBM38.
• Utilized cancer cell lines to evaluate the effects of ANGEL2 loss on cell growth and chemoresistance.
• Administered an ANGEL2-derived peptide (Pep7) to assess its therapeutic potential.

Main Results:

• Loss of ANGEL2 significantly decreased the expression of the tumor suppressor protein TP53.
• ANGEL2 directly binds to EIF4E, inhibiting the interaction of RBM38 with EIF4E and thereby enhancing TP53 translation.
• Depletion of ANGEL2 in cancer cells led to increased spheroid growth and resistance to doxorubicin and etoposide.
• Treatment with the Pep7 peptide restored wildtype TP53 expression and sensitized cancer cells to doxorubicin.

Conclusions:

• ANGEL2 plays a crucial role in cancer by modulating the EIF4E-RBM38 complex to promote wildtype TP53 translation.
• Loss of ANGEL2 contributes to chemoresistance through decreased TP53 translation.
• The ANGEL2-derived peptide Pep7 shows therapeutic potential for treating cancers with wildtype TP53 expression.